-- Earnings Flash (ARAV) ARAVIVE Posts Q2 Revenue $1.6M
7:01AM ET 8/11/2022 MT Newswires...
Quotes Snapshot > ARAV
Aravive Inc ARAV:NASDAQ
Last Price$0.90NASDAQ Previous Close - Last Trade as of 4:00PM ET 8/12/22
Today's Change0(0.00%)
Bid (Size)$0.85 (20)
Ask (Size)$0.94 (26)
Day Low / HighN/A - N/A
Volume127.5 K
Read more news Recent News
Roth Capital Initiates Aravive at Buy with $15 Price Target
10:35AM ET 6/03/2022 MT NewswiresAravive (ARAV) has an average rating of buy and price targets ranging from $6 to $26, according to analysts polled by Capital IQ. (MT Newswires covers...
Aravive Appoints Rudy Howard as CFO
7:13AM ET 6/03/2022 MT NewswiresAravive (ARAV) said Friday that it has appointed Rudy Howard as chief financial officer, effective immediately. Vinay Shah has stepped down as CFO for...
Piper Sandler Adjusts Aravive's Price Target to $6 From $9, Reiterates Overweight Rating
5:10AM ET 5/13/2022 MT NewswiresAravive (ARAV) has an average rating of buy and price targets ranging from $6 to $26, according to analysts polled by Capital IQ. (MT Newswires covers...
View all Commentary and Analysis
Aravive (ARAV) Investor presentations - Slideshow
11:53AM ET 5/25/2022 Seeking AlphaCompany Profile
Business DescriptionAravive, Inc. operates as a clinical stage biotechnology company. The firm engages in the development of new therapies that target important survival pathways for both advanced solid tumors as well as hematologic malignancies. Its product candidate, Aravive-S6, is a soluble Fc-fusion protein designed to block the activation of the GAS6-AXL signaling pathway by intercepting the binding of GAS6 to its receptor AXL which also promotes metastasis, cancer cell survival, resistance to treatments and immune suppression. The company was founded on December 10, 2008 and is headquartered in Houston, TX. View company web site for more details
| Address | River Oaks Tower Houston, Texas 77098 |
| Phone | +1.936.355.1910 |
| Number of Employees | 14 |
| President, Chief Executive Officer & Director | Gail Frances McIntyre |
| Chief Operating Officer | Leonard Scott Dove |
| Chief Financial & Accounting Officer | Rudy C. Howard |
| Chief Medical Officer | Robert B. Geller |
Company Highlights
| Price Open | $0.95 |
| Previous Close | $0.93 |
| 52 Week Range | $0.80 - 4.40 |
| Market Capitalization | $27.3 M |
| Shares Outstanding | 30.5 M |
| Sector | Health Technology |
| Industry | Biotechnology | Next Earnings Announcement | 10/27/2022 |
Options Summary
| Call Open Interest (1d)* |  |
| Put Open Interest (1d)* | |
| Call Volume (1d)* | |
| Put Volume (1d)* | |
| Put Call Open Interest Ratio (1d)* | |
| Put Call Volume Ratio (1d)* | |
| * Data delayed by up to 15 minutes |
View all fundamentalsFundamentals
| Price / Earnings | N/A |
| Earnings per Share | -$2.42 |
| Beta vs. S&P 500 | N/A |
| Revenue | $1.4 M |
| Net Profit Margin | -910.48% |
| Return on Equity | -134.06% |
Analyst Ratings as of 06/02/2022
| Buy | |
| Overweight | |
| Hold | |
| Underweight | |
| Sell | |
Consensus Recommendation | |